National Institute of Allergy and Infectious Diseases Cancellation of Meeting, 50680 [2014-20057]

Download as PDF 50680 Federal Register / Vol. 79, No. 164 / Monday, August 25, 2014 / Notices emcdonald on DSK67QTVN1PROD with NOTICES status/Pages/status.aspx. The NIH is required by the BPCA to update the priority list every three years. This publication serves as an update to the BPCA priority list of needs in pediatric therapeutics. The Obstetric and Pediatric Pharmacology and Therapeutics Branch of the NICHD developed a prioritization process for the determination of the needs in pediatric therapeutics. There are two main phases in this process. Phase I of the prioritization process entails identifying therapeutic areas, which are general categories of conditions, diseases, settings of care, or populations with multiple therapeutic needs. The NICHD solicits input from experts in the pediatric research, general pediatric and subspecialty care, and patient advocacy groups to determine these therapeutic areas that need further study. At the beginning of every year, the NICHD revisits the current list of needs in pediatric therapeutics, prioritizes three therapeutic areas of interest for that calendar year, and develops working groups in the prioritized areas. Recommendations from the therapeutic area working groups are then presented to the NICHD and the FDA at the end of the calendar year at the Institute’s annual BPCA meeting. Previous meeting minutes can be found on the BPCA Web site: https://bpca.nichd.nih.gov/prioritization/ meetings/Pages/index.aspx. Phase II of the prioritization process entails an extensive review and ranking of all nominations received based on key criteria for prioritization, such as relevance, label gaps, affected population, and feasibility. Please visit the BPCA Web site for more details: (https://bpca.nichd.nih.gov/ prioritization/priority_list/Pages/ priority_list.aspx). Below is an updated list of therapeutic areas and drugs that have been prioritized for study since the inception of the BPCA and a summary of the NICHD’s plans and progress in all of these areas to date. The NICHD welcomes input from the pediatric medical community on additional gaps in pediatric therapeutics for future consideration. All nominations should be submitted to Dr. Perdita TaylorZapata (contact information below). Priority List of Needs in Pediatric Therapeutics 2014 In accordance with the BPCA legislation, the list outlines priority needs in pediatric therapeutics for multiple therapeutic areas listed below. The complete list can be found on the BPCA Web site at the following address: https://bpca.nichd.nih.gov. VerDate Mar<15>2010 17:31 Aug 22, 2014 Jkt 232001 D Table 1: Infectious Disease Priorities D Table 2: Cardiovascular Disease Priorities D Table 3: Respiratory Disease Priorities D Table 4: Intensive Care Priorities D Table 5: Bio-Defense Research Priorities D Table 6: Pediatric Cancer Priorities D Table 7: Psychiatric Disorder Priorities D Table 8: Neurological Disease Priorities D Table 9: Neonatal Research Priorities D Table 10: Adolescent Research Priorities D Table 11: Hematologic Disease Priorities D Table 12: Endocrine Disease Priorities and Diseases With Limited Alternative Therapies D Table 13: Dermatologic Disease Priorities D Table 14: Gastrointestinal Disease Priorities D Table 15: Renal Disease Priorities D Table 16: Rheumatologic Disease Priorities D Table 17: Special Considerations We would like for you to save the date of December 10, 2014, for our annual BPCA stakeholders meeting. The meeting will be held at the Natcher Auditorium on the NIH campus in Bethesda, Maryland, and will be streamed live via videocast for all nonlocal attendees. FOR FURTHER INFORMATION CONTACT: Dr. Perdita Taylor-Zapata via email at taylorpe@mail.nih.gov; by phone at 301–496–9584; or by fax at 301–480– 2897. Dated: August 18, 2014. Francis S. Collins, Director, National Institutes of Health. [FR Doc. 2014–20156 Filed 8–22–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases Cancellation of Meeting Notice is hereby given of the cancellation of the National Institute of Allergy and Infectious Diseases Special Emphasis Panel, September 10, 2014, 10:00 a.m. to September 10, 2014, 12:00 p.m., National Institutes of Health, 6700B Rockledge Drive, Room 3124, Bethesda, MD 20817 which was published in the Federal Register on August 15, 2014, 79FR48173. The Review Committee will not meet because the application was withdrawn. PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 Dated: August 19, 2014. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2014–20057 Filed 8–22–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, Ancillary Studies to the NIDDK IBDGC. Date: October 16, 2014. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Dianne Camp, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 756, 6707, Democracy Boulevard, Bethesda, MD 20892–2542, 301–594–7682, campd@extra.niddk.nih.gov. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases, Special Emphasis Panel, Small Grants for New Investigators to Promote Diversity. Date: October 30, 2014. Time: 12:00 p.m. to 2:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Barbara A. Woynarowska, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 754, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 402–7172, woynarowskab@niddk.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, E:\FR\FM\25AUN1.SGM 25AUN1

Agencies

[Federal Register Volume 79, Number 164 (Monday, August 25, 2014)]
[Notices]
[Page 50680]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-20057]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases 
Cancellation of Meeting

    Notice is hereby given of the cancellation of the National 
Institute of Allergy and Infectious Diseases Special Emphasis Panel, 
September 10, 2014, 10:00 a.m. to September 10, 2014, 12:00 p.m., 
National Institutes of Health, 6700B Rockledge Drive, Room 3124, 
Bethesda, MD 20817 which was published in the Federal Register on 
August 15, 2014, 79FR48173.
    The Review Committee will not meet because the application was 
withdrawn.

    Dated: August 19, 2014.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-20057 Filed 8-22-14; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.